NCT03442244

Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

Skin Irritation Trial of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: Male
• Age: 20 Years – 40 Years
• Healthy volunteers: Accepted

Summary

This trial is looking at whether the LEO 90100 foam causes irritation of the skin in healthy Japanese male adults without psoriasis. A single application of LEO 90100 foam and its vehicle will each be made to 2 body sites in 20 subjects.

Conditions

• Psoriasis Vulgaris

Interventions

Type	Name	Description
DRUG	LEO 90100 foam	Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
DRUG	Vehicle of LEO 90100 foam	Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back

Timeline

• Start date: 2018-01-30
• Primary completion: 2018-02-20
• Completion: 2018-02-20
• First posted: 2018-02-22
• Last updated: 2025-02-24

Locations

1 site across 1 country: Japan